The Committee for Medicinal products for Human Use (CHMP) decided that NeoSpect’ s benefits are greater than its risks for the scintigraphic imaging of suspected malignant lung tumours in the lung after initial detection, in combination with CT scan or chest X-ray, in patients with solitary pulmonary nodules.